SG11201701342XA - Conjugates and conjugating reagents - Google Patents
Conjugates and conjugating reagentsInfo
- Publication number
- SG11201701342XA SG11201701342XA SG11201701342XA SG11201701342XA SG11201701342XA SG 11201701342X A SG11201701342X A SG 11201701342XA SG 11201701342X A SG11201701342X A SG 11201701342XA SG 11201701342X A SG11201701342X A SG 11201701342XA SG 11201701342X A SG11201701342X A SG 11201701342XA
- Authority
- SG
- Singapore
- Prior art keywords
- conjugates
- conjugating reagents
- conjugating
- reagents
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1418984.9A GB2531715A (en) | 2014-10-24 | 2014-10-24 | Novel drug conjugates |
| GBGB1418989.8A GB201418989D0 (en) | 2014-10-24 | 2014-10-24 | Novel conjugation process and reagents |
| GBGB1418986.4A GB201418986D0 (en) | 2014-10-24 | 2014-10-24 | Novel conjugates and novel conjugating reagents |
| PCT/GB2015/052953 WO2016063006A1 (en) | 2014-10-24 | 2015-10-08 | Conjugates and conjugating reagents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201701342XA true SG11201701342XA (en) | 2017-03-30 |
Family
ID=54337308
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201701342XA SG11201701342XA (en) | 2014-10-24 | 2015-10-08 | Conjugates and conjugating reagents |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20170290925A1 (en) |
| EP (1) | EP3220956B1 (en) |
| JP (1) | JP6612860B2 (en) |
| KR (1) | KR102513926B1 (en) |
| CN (1) | CN107073131B (en) |
| AU (1) | AU2015334717B2 (en) |
| BR (1) | BR112017005760A2 (en) |
| CA (1) | CA2963043A1 (en) |
| ES (1) | ES2960741T3 (en) |
| IL (1) | IL250644B (en) |
| MX (1) | MX2017005199A (en) |
| RU (1) | RU2017108448A (en) |
| SG (1) | SG11201701342XA (en) |
| WO (1) | WO2016063006A1 (en) |
| ZA (1) | ZA201701337B (en) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10098960B2 (en) | 2015-04-03 | 2018-10-16 | Ucl Business Plc | Polymer conjugate |
| CN116478293A (en) | 2016-01-12 | 2023-07-25 | 克雷森多生物制剂有限公司 | Therapeutic molecules |
| WO2017161206A1 (en) | 2016-03-16 | 2017-09-21 | Halozyme, Inc. | Conjugates containing conditionally active antibodies or antigen-binding fragments thereof, and methods of use |
| WO2017178828A1 (en) | 2016-04-14 | 2017-10-19 | Polytherics Limited | Conjugates and conjugating reagents comprising a linker that includes at least two (-ch2-ch2-0-) units in a ring |
| GB201608936D0 (en) * | 2016-05-20 | 2016-07-06 | Polytherics Ltd | Novel conjugates and novel conjugating reagents |
| WO2017212250A1 (en) | 2016-06-06 | 2017-12-14 | Polytherics Limited | Antibodies, uses thereof and conjugates thereof |
| GB201614162D0 (en) * | 2016-08-18 | 2016-10-05 | Polytherics Ltd | Antibodies, uses thereof and conjugates thereof |
| GB201615725D0 (en) | 2016-09-15 | 2016-11-02 | Polytherics Ltd | Novel cytotoxic agents and conjugates thereof |
| KR102464270B1 (en) | 2017-03-30 | 2022-11-07 | 니치유 가부시키가이샤 | Heterobifunctional monodisperse polyethylene glycol and complex using same |
| GB201711068D0 (en) | 2017-07-10 | 2017-08-23 | Crescendo Biologics Ltd | Therapeutic molecules binding PSMA |
| CA3093645A1 (en) | 2018-03-13 | 2019-09-19 | Nof Corporation | Heterobifunctional compound having monodispersed polyethylene glycol in main chain and side chain |
| EP3789401A1 (en) | 2019-09-03 | 2021-03-10 | Gamamabs Pharma | Amhrii-binding antibody drug conjugates and their use thereof in the treatment of cancers |
| GB2594753B (en) | 2020-05-27 | 2022-05-18 | Spirea Ltd | Antibody-drug conjugates |
| WO2023047090A1 (en) | 2021-09-21 | 2023-03-30 | Spirea Limited | Antibody-drug conjugates |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5446090A (en) * | 1993-11-12 | 1995-08-29 | Shearwater Polymers, Inc. | Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules |
| ATE399809T1 (en) * | 1998-03-12 | 2008-07-15 | Nektar Therapeutics Al Corp | METHOD FOR PRODUCING POLYMER CONJUGATES |
| KR100511749B1 (en) * | 2001-11-06 | 2005-09-02 | 선바이오(주) | Modified interferon-beta, and chemically modified conjugates thereof |
| BR122018071968B8 (en) * | 2003-11-06 | 2021-07-27 | Seattle Genetics Inc | antibody-drug conjugate, pharmaceutical composition, article of manufacture and use of an antibody-drug conjugate |
| US8158590B2 (en) * | 2005-08-05 | 2012-04-17 | Syntarga B.V. | Triazole-containing releasable linkers, conjugates thereof, and methods of preparation |
| US20070141134A1 (en) * | 2005-12-16 | 2007-06-21 | Kosak Matthew K | Shielded micelles for polynucleotide delivery |
| RU2009114154A (en) * | 2006-09-15 | 2010-10-20 | Энзон Фармасьютикалз, Инк. (Us) | POLYMERIC DRUGS WITH DIRECTED DELIVERY CONTAINING POLYFUNCTIONAL LINKERS |
| EP2118150B1 (en) * | 2007-02-14 | 2015-09-23 | Biocompatibles UK Limited | Derivatisation of biological molecules |
| GB0922354D0 (en) * | 2009-12-21 | 2010-02-03 | Polytherics Ltd | Novel polymer conjugates |
| PL2678037T3 (en) * | 2011-02-25 | 2015-05-29 | Lonza Ag | Branched linker for protein drug conjugates |
| CN104906592B (en) * | 2011-02-25 | 2017-11-03 | 广州南沙龙沙有限公司 | Side chain connected body for pharmaceutical grade protein conjugate |
| US9650331B2 (en) * | 2012-06-18 | 2017-05-16 | Polytherics Limited | Conjugation reagents |
| GB201210770D0 (en) * | 2012-06-18 | 2012-08-01 | Polytherics Ltd | Novel conjugation reagents |
| IN2014DN10428A (en) * | 2012-06-19 | 2015-08-21 | Polytherics Ltd | |
| IN2015DN02349A (en) * | 2012-10-24 | 2015-08-28 | Polytherics Ltd | |
| NO2789793T3 (en) * | 2012-10-24 | 2018-01-27 | ||
| HUE051389T2 (en) * | 2013-10-15 | 2021-03-01 | Seagen Inc | Pegylated drug-linkers for improved ligand-drug conjugate pharmacokinetics |
-
2015
- 2015-10-08 ES ES15782051T patent/ES2960741T3/en active Active
- 2015-10-08 CN CN201580057559.0A patent/CN107073131B/en active Active
- 2015-10-08 KR KR1020177010432A patent/KR102513926B1/en active IP Right Grant
- 2015-10-08 WO PCT/GB2015/052953 patent/WO2016063006A1/en active Application Filing
- 2015-10-08 JP JP2017519672A patent/JP6612860B2/en active Active
- 2015-10-08 RU RU2017108448A patent/RU2017108448A/en unknown
- 2015-10-08 CA CA2963043A patent/CA2963043A1/en not_active Abandoned
- 2015-10-08 AU AU2015334717A patent/AU2015334717B2/en active Active
- 2015-10-08 SG SG11201701342XA patent/SG11201701342XA/en unknown
- 2015-10-08 MX MX2017005199A patent/MX2017005199A/en unknown
- 2015-10-08 US US15/517,969 patent/US20170290925A1/en not_active Abandoned
- 2015-10-08 EP EP15782051.5A patent/EP3220956B1/en active Active
- 2015-10-08 BR BR112017005760A patent/BR112017005760A2/en not_active Application Discontinuation
-
2017
- 2017-02-16 IL IL250644A patent/IL250644B/en active IP Right Grant
- 2017-02-22 ZA ZA2017/01337A patent/ZA201701337B/en unknown
-
2020
- 2020-03-03 US US16/807,298 patent/US20200268885A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR102513926B1 (en) | 2023-03-23 |
| US20200268885A1 (en) | 2020-08-27 |
| BR112017005760A2 (en) | 2017-12-12 |
| AU2015334717B2 (en) | 2021-02-25 |
| IL250644B (en) | 2020-10-29 |
| WO2016063006A1 (en) | 2016-04-28 |
| MX2017005199A (en) | 2017-07-26 |
| CA2963043A1 (en) | 2016-04-28 |
| JP6612860B2 (en) | 2019-11-27 |
| RU2017108448A (en) | 2018-11-27 |
| ZA201701337B (en) | 2018-05-30 |
| JP2017537062A (en) | 2017-12-14 |
| CN107073131B (en) | 2021-05-25 |
| EP3220956B1 (en) | 2023-08-09 |
| ES2960741T3 (en) | 2024-03-06 |
| KR20170075724A (en) | 2017-07-03 |
| IL250644A0 (en) | 2017-06-29 |
| US20170290925A1 (en) | 2017-10-12 |
| EP3220956A1 (en) | 2017-09-27 |
| CN107073131A (en) | 2017-08-18 |
| AU2015334717A1 (en) | 2017-04-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL258248A (en) | Affinity-oligonucleotide conjugates and uses thereof | |
| IL290457A (en) | Antibodies and conjugates thereof | |
| ZA201701337B (en) | Conjugates and conjugating reagents | |
| IL248961A0 (en) | Auristatin derivatives and conjugates thereof | |
| ZA201607385B (en) | Anti-ptk7 antibody-drug conjugates | |
| IL252015A0 (en) | Antibody drug conjugates | |
| ZA201704297B (en) | Pyrrolobenzodiazepine-antibody conjugates | |
| IL250189A0 (en) | Anti-cdh6 antibody drug conjugates | |
| PL3119885T3 (en) | Antibody-fynomer conjugates | |
| GB201416112D0 (en) | Pyrrolobenzodiazepines and conjugates thereof | |
| IL265471A (en) | Affinity-oligonucleotide conjugates and uses thereof | |
| IL258759A (en) | Anti-cd3-folate conjugates and their uses | |
| ZA201608327B (en) | Curcumin-peptide conjugates and formulations thereof | |
| GB201608936D0 (en) | Novel conjugates and novel conjugating reagents | |
| PT3544637T (en) | Nomv-antigen conjugates and use thereof | |
| GB201504694D0 (en) | Covalent conjugates | |
| GB201601004D0 (en) | Nanoparticle conjugates | |
| IL246794A0 (en) | No-releasing nitrooxy-chromene conjugates | |
| GB201418986D0 (en) | Novel conjugates and novel conjugating reagents | |
| GB201604808D0 (en) | Novel compounds and novel conjugating reagents | |
| GB201603124D0 (en) | Novel compounds and conjugates | |
| GB201420910D0 (en) | Pyrrolobenzodiazepine-antibody conjugates | |
| GB201406718D0 (en) | Pyrrolobenzodiazepine-antibody conjugates | |
| GB201406720D0 (en) | Pyrrolobenzodiazepine-antibody conjugates | |
| GB201406719D0 (en) | Pyrrolobenzodiaepine-antibody conjugates |